NASDAQ:FOMX - Foamix Pharmaceuticals Stock Price, News & Analysis

$3.50
+0.08 (+2.34 %)
(As of 09/15/2019 04:00 PM ET)
Today's Range
$3.41
Now: $3.50
$3.54
50-Day Range
$2.02
MA: $2.86
$3.62
52-Week Range
$1.97
Now: $3.50
$6.42
Volume481,520 shs
Average Volume709,595 shs
Market Capitalization$213.50 million
P/E RatioN/A
Dividend YieldN/A
Beta1.53
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. Read More…

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FOMX
CUSIPN/A
Phone972-8931-6233

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.60 million
Book Value$1.70 per share

Profitability

Net Income$-74,160,000.00
Net Margins-2,115.11%

Miscellaneous

Employees80
Market Cap$213.50 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive FOMX News and Ratings via Email

Sign-up to receive the latest news and ratings for FOMX and its competitors with MarketBeat's FREE daily newsletter.


Foamix Pharmaceuticals (NASDAQ:FOMX) Frequently Asked Questions

What is Foamix Pharmaceuticals' stock symbol?

Foamix Pharmaceuticals trades on the NASDAQ under the ticker symbol "FOMX."

How were Foamix Pharmaceuticals' earnings last quarter?

Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) announced its quarterly earnings data on Wednesday, August, 7th. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.07. Foamix Pharmaceuticals had a negative return on equity of 75.99% and a negative net margin of 2,115.11%. View Foamix Pharmaceuticals' Earnings History.

When is Foamix Pharmaceuticals' next earnings date?

Foamix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Foamix Pharmaceuticals.

What price target have analysts set for FOMX?

5 equities research analysts have issued 1 year target prices for Foamix Pharmaceuticals' shares. Their forecasts range from $10.00 to $30.00. On average, they expect Foamix Pharmaceuticals' share price to reach $15.60 in the next twelve months. This suggests a possible upside of 345.7% from the stock's current price. View Analyst Price Targets for Foamix Pharmaceuticals.

What is the consensus analysts' recommendation for Foamix Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Foamix Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Foamix Pharmaceuticals.

What are Wall Street analysts saying about Foamix Pharmaceuticals stock?

Here are some recent quotes from research analysts about Foamix Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company. It develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. The Company's lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo. It has operations primarily in the United States, Germany, and Israel. Foamix Pharmaceuticals Ltd. is headquartered in Rehovot, Israel. " (8/22/2019)
  • 2. Cantor Fitzgerald analysts commented, ": Post a solid quarter of execution and ahead of two potential launches for the company, we reiterate our OW rating and 12-month PT of $15 for FOMX shares. We continue to recommend FOMX as one of our top ideas for 2019 because we think its two de-risked assets, FMX101 and FMX103, as well as additional new opportunities that leverage FOMX’s technology are all underappreciated. Therefore, upward earnings revisions should drive the stock higher. FOMX’s earnings call is 8:30AM ET tomorrow." (5/7/2019)

Has Foamix Pharmaceuticals been receiving favorable news coverage?

News coverage about FOMX stock has been trending somewhat positive recently, InfoTrie reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Foamix Pharmaceuticals earned a news impact score of 0.9 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Foamix Pharmaceuticals.

Who are some of Foamix Pharmaceuticals' key competitors?

What other stocks do shareholders of Foamix Pharmaceuticals own?

Who are Foamix Pharmaceuticals' key executives?

Foamix Pharmaceuticals' management team includes the folowing people:
  • Mr. David T. Domzalski, CEO & Director (Age 52)
  • Mr. Ilan Hadar M.B.A., MBA, CFO & Country Mang. (Age 50)
  • Ms. Mutya Harsch, Gen. Counsel & Chief Legal Officer (Age 44)
  • Dr. Darrell S. Rigel M.D., MS, Consultant (Age 69)
  • Dr. Iain A. Stuart, Chief R&D Officer (Age 46)

Who are Foamix Pharmaceuticals' major shareholders?

Foamix Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include AXA (2.20%), Sofinnova Investments Inc. (1.83%), Stonepine Capital Management LLC (1.07%), BlackRock Inc. (0.89%), DLD Asset Management LP (0.86%) and First Manhattan Co. (0.71%). Company insiders that own Foamix Pharmaceuticals stock include Aharon Schwartz, Alvin D Howard, Anna Kazanchyan, David Domzalski, Iain Stuart, Ilan Hadar, Matthew T Wiley, Meir Eini, Mutya Harsch, Russell P Elliott and Stanley Hirsch. View Institutional Ownership Trends for Foamix Pharmaceuticals.

Which institutional investors are selling Foamix Pharmaceuticals stock?

FOMX stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Bank of New York Mellon Corp, Stonepine Capital Management LLC, BlackRock Inc., First Manhattan Co., Eversept Partners LP, Wells Fargo & Company MN and AXA. Company insiders that have sold Foamix Pharmaceuticals company stock in the last year include Alvin D Howard, Anna Kazanchyan, David Domzalski, Iain Stuart, Ilan Hadar, Mutya Harsch and Russell P Elliott. View Insider Buying and Selling for Foamix Pharmaceuticals.

Which institutional investors are buying Foamix Pharmaceuticals stock?

FOMX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Sofinnova Investments Inc., DLD Asset Management LP, ARK Investment Management LLC, ETF Managers Group LLC, JPMorgan Chase & Co., Delek Group Ltd. and Worth Venture Partners LLC. Company insiders that have bought Foamix Pharmaceuticals stock in the last two years include Aharon Schwartz and Matthew T Wiley. View Insider Buying and Selling for Foamix Pharmaceuticals.

How do I buy shares of Foamix Pharmaceuticals?

Shares of FOMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Foamix Pharmaceuticals' stock price today?

One share of FOMX stock can currently be purchased for approximately $3.50.

How big of a company is Foamix Pharmaceuticals?

Foamix Pharmaceuticals has a market capitalization of $213.50 million and generates $3.60 million in revenue each year. The specialty pharmaceutical company earns $-74,160,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Foamix Pharmaceuticals employs 80 workers across the globe.View Additional Information About Foamix Pharmaceuticals.

What is Foamix Pharmaceuticals' official website?

The official website for Foamix Pharmaceuticals is http://www.foamix.com/.

How can I contact Foamix Pharmaceuticals?

Foamix Pharmaceuticals' mailing address is 2 HOLZMAN ST. WEIZMANN SCIENCE PARK, REHOVOT L3, 76704. The specialty pharmaceutical company can be reached via phone at 972-8931-6233 or via email at [email protected]


MarketBeat Community Rating for Foamix Pharmaceuticals (NASDAQ FOMX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  210 (Vote Outperform)
Underperform Votes:  221 (Vote Underperform)
Total Votes:  431
MarketBeat's community ratings are surveys of what our community members think about Foamix Pharmaceuticals and other stocks. Vote "Outperform" if you believe FOMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel